Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines

The goal of this study is to learn whether different types of vaccines to prevent bacterial infections are able to effectively create antibodies that defend against certain types of bacteria. We will give two different types of vaccine and evaluate the effectiveness of antibodies produced by each vaccine in killing bacteria.

NCT Number	NCT07135453
Lead Sponsor	University of Alabama at Birmingham Collaborators: Merck Sharp & Dohme LLC
Conditions	Vaccine, Pneumococcal Disease
Enrollment	70 participants
Start Date	2026-07
Primary Completion	2027-03 (estimated)
Study Completion	2027-08 (estimated)
Updated on ClinicalTrials.gov	2026-07-09